Escamilla Raul, Camarena Beatriz, Saracco-Alvarez Ricardo, Fresán Ana, Hernández Sandra, Aguilar-García Alejandro
Schizophrenia Clinic, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz (INPRFM), Mexico City, Mexico.
Department of Pharmacogenetics, INPRFM, Mexico City, Mexico,
Neuropsychiatr Dis Treat. 2018 Nov 5;14:2981-2987. doi: 10.2147/NDT.S176455. eCollection 2018.
The efficacy of schizophrenia treatments using antipsychotics (APs) has long been established, but the benefit obtained by several patients using conventional APs (typical or atypical) has not been enough. Currently, the genetic study of the primary mechanisms of action of the APs has been focused on the dopaminergic pathways. The objective of this study was to determine if the response phenotypes (responder, resistance to treatment, and ultra-resistance to treatment groups) are associated with six single-nucleotide polymorphisms: (Val158Met), (A-241G, C376G, C939T, Taq1A), and (Ser9Gly).
We classified the patients through a retrospective/prospective methodology to define response phenotypes.
/Val158Met and /Ser9Gly were associated with the responder group (<0.05). The single-nucleotide polymorphism A-241G of gene was related with the resistant-to-treatment group (<0.001). Finally, Met/Met of and Ser/Gly of genes showed a predictive effect associated with the resistant-to-treatment phenotype.
Further analyses should be performed to validate these genetic markers as mediators for the response to APs.
使用抗精神病药物(APs)治疗精神分裂症的疗效早已得到证实,但一些患者使用传统APs(典型或非典型)所获得的益处并不充分。目前,关于APs主要作用机制的遗传学研究一直聚焦于多巴胺能途径。本研究的目的是确定反应表型(反应者、治疗抵抗和超治疗抵抗组)是否与六个单核苷酸多态性相关:(Val158Met)、(A - 241G、C376G、C939T、Taq1A)以及(Ser9Gly)。
我们通过回顾性/前瞻性方法对患者进行分类以定义反应表型。
/Val158Met和/Ser9Gly与反应者组相关(<0.05)。基因的单核苷酸多态性A - 241G与治疗抵抗组相关(<0.001)。最后,基因Met/Met和基因Ser/Gly显示出与治疗抵抗表型相关的预测作用。
应进行进一步分析以验证这些遗传标记作为对APs反应的介导因素。